U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07286656) titled 'A Study of GensSci098 in Subjects With Graves' Disease' on Dec. 03.
Brief Summary: To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
Study Start Date: Dec. 09
Study Type: INTERVENTIONAL
Condition:
Safety
Tolerability
GenSci098
Graves Disease
Intervention:
DRUG: GenSci098
* Administration: Only one dose of GenSci098 will be given.
* Route of Administration: Subcutaneous (injected under the skin).
* Dose Levels: * Dose 1 * Dose 2* Dose 3* Dose 4
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Disclaimer...